Michael R Clark

Awards Nomination 20+ Million Readerbase

PMC/PubMed Indexed Articles

Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation

MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA

Google Scholar citation report

Citations : 2051

Journal of Vaccines & Vaccination received 2051 citations as per Google Scholar report

Journal of Vaccines & Vaccination peer review process verified at publons

25+ Million Website Visitors

Indexed In

Academic Journals Database
Open J Gate
Genamics JournalSeek
JournalTOCs
China National Knowledge Infrastructure (CNKI)
Scimago
Ulrich's Periodicals Directory
RefSeek
Hamdard University
EBSCO A-Z
OCLC- WorldCat
Publons
MIAR
University Grants Commission
Geneva Foundation for Medical Education and Research
Euro Pub
Google Scholar

Useful Links

Share This Page

Tweets by Vaccine41931315

Open Access Journals

Michael R Clark

Michael R Clark

Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, United Kingdom

Biography

Mike Clark is a Immunologist and Antibody Engineering Consultant, co-owner & managing director at Clark Antibodies Ltd in University of Cambridg, united kingdo. his Extensive experience of the development of antibody based therapeutics including recombinant and bispecific antibodies. An inventor of the first fully humanised antibody CAMPATH (alemtuzumab) and several other humanised therapeutic antibodies to antigens such as CD3 (TRX4 otelixizumab) and CD4 (TRX1).